Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash & Current Investments (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Cash & Current Investments readings, the most recent being $51.3 million for Q1 2026.

  • Quarterly Cash & Current Investments rose 41.33% to $51.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $51.3 million through Mar 2026, up 41.33% year-over-year, with the annual reading at $59.9 million for FY2025, 35.66% up from the prior year.
  • Cash & Current Investments hit $51.3 million in Q1 2026 for DiaMedica Therapeutics, down from $59.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $59.9 million in Q4 2025 and bottomed at $2.8 million in Q3 2022.
  • Average Cash & Current Investments over 5 years is $39.8 million, with a median of $44.1 million recorded in 2024.
  • The largest annual shift saw Cash & Current Investments crashed 94.22% in 2022 before it soared 1571.4% in 2023.
  • DiaMedica Therapeutics' Cash & Current Investments stood at $33.5 million in 2022, then skyrocketed by 57.89% to $52.9 million in 2023, then decreased by 16.54% to $44.1 million in 2024, then skyrocketed by 35.66% to $59.9 million in 2025, then dropped by 14.29% to $51.3 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Cash & Current Investments are $51.3 million (Q1 2026), $59.9 million (Q4 2025), and $55.3 million (Q3 2025).